MET Form 4: Director William Kennard adds 312 shares at $79.29

Rhea-AI Filing Summary

MetLife director William E. Kennard reported an imputed reinvestment of dividends that resulted in the acquisition of 312 shares of MetLife common stock at an implied price of $79.29 per share on 09/09/2025. After this transaction he beneficially owns 43,918 shares, held directly and indirectly, with indirect holdings attributable to shares held in the MetLife Policyholder Trust. The filing notes the acquisition arose from the Deferred Compensation Plan for Non-Management Directors, where payable shares were deferred and reinvested.

Insights

Corporate Governance Expert

TL;DR: A routine dividend reinvestment increased a director's stake modestly; no unusual trading or material change in control.

This Form 4 documents a standard imputed dividend reinvestment under the non-management directors' deferred compensation plan, resulting in 312 shares added at an implied price of $79.29. The transaction is employer-plan driven rather than active discretionary trading by the director, which reduces concerns about opportunistic insider timing. Beneficial ownership remains modest at 43,918 shares and includes indirect trust holdings for policyholders.

Securities Analyst

TL;DR: Minor, non-disruptive change in insider holdings from routine plan mechanics; unlikely to move investor valuation.

The reported acquisition is small relative to institutional scales and is identified as an imputed reinvestment of dividends, not a purchased open-market stake. The disclosure clarifies direct and indirect ownership via the MetLife Policyholder Trust, which is administrative. There are no derivative transactions or disposals reported, and the filing contains no signals of material corporate events.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Kennard William E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	312	$79.29	$25K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 43,918 shares (Direct); Common Stock — 10 shares (Indirect, By the MetLife Policyholder Trust)

Footnotes (1)

1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. Shares held in trust under the MetLife Policyholder Trust established to hold shares of common stock allocated to eligible policyholders of Metropolitan Life Insurance Company, a wholly-owned subsidiary of MetLife, Inc.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kennard William E

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NY 10166

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		A(1)		312	A	$79.29	43,918	D
Common Stock								10	I	By the MetLife Policyholder Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

2. Shares held in trust under the MetLife Policyholder Trust established to hold shares of common stock allocated to eligible policyholders of Metropolitan Life Insurance Company, a wholly-owned subsidiary of MetLife, Inc.

Remarks:

	/s/ Taylor McInerney Jansen, Attorney-in-fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did MetLife director William Kennard report on Form 4 for MET?

He reported an imputed reinvestment of dividends that resulted in the acquisition of 312 shares of MetLife common stock.

At what price were the 312 shares reported on the Form 4 for MET?

The shares are shown with an implied price of $79.29 per share.

How many MetLife shares does the reporting person beneficially own after the transaction?

The Form 4 reports 43,918 shares beneficially owned following the transaction.

Why were the shares acquired according to the Form 4?

The filing states the acquisition was due to imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors.

Are any shares held indirectly by the reporting person?

Yes. Some shares are held indirectly through the MetLife Policyholder Trust, which holds shares allocated to eligible policyholders of a MetLife subsidiary.